Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.39 |
| ▸ | ALB | P02768 | 3/20 | 0.38 |
| ▸ | CASP2 | P42575 | 1/20 | 0.36 |
| ▸ | NAAA | Q02083 | 1/20 | 0.34 |
| ▸ | GLP1R | P43220 | 8/20 | 0.34 |
| ▸ | MMP2 | P08253 | 2/20 | 0.33 |
| ▸ | MMP9 | P14780 | 2/20 | 0.33 |
| ▸ | MMP8 | P22894 | 2/20 | 0.33 |
| ▸ | MMP12 | P39900 | 2/20 | 0.33 |
| ▸ | MMP14 | P50281 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21913856 | 0.96 | ALDH1A1 (0.43) | ALDH1A1FOLH1ALBCASP2NAAA | |
| SCHEMBL14952664 | 0.90 | ALDH1A1 (0.41) | ALDH1A1FOLH1ALBCASP2NAAA | |
| SCHEMBL21899464 | 0.88 | ALDH1A1 (0.42) | ALDH1A1FOLH1ALBCASP2NAAA | |
| SCHEMBL16409459 | 0.87 | CASP2 (0.51) | ALDH1A1ALBCASP2NAAAMMP8 | |
| SCHEMBL20729996 | 0.86 | ALB (0.38) | ALDH1A1FOLH1ALBCASP2NAAA | |
| SCHEMBL16248536 | 0.86 | NAMPT (0.40) | ALDH1A1ALBCASP2NAAAMEN1 | |
| SCHEMBL25129545 | 0.86 | ALDH1A1 (0.37) | ALDH1A1FOLH1ALBCASP2NAAA | |
| SCHEMBL16231545 | 0.86 | FOLH1 (0.42) | ALDH1A1FOLH1ALBCASP2NAAA | |
| SCHEMBL13461485 | 0.86 | CASP2 (0.54) | CASP2NAAAMMP2MMP9MMP8 | |
| SCHEMBL25132901 | 0.84 | ALB (0.37) | ALDH1A1FOLH1ALBCASP2NAAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210324006-A1 | PEPTIDE COMPOSITIONS AND METHODS FOR INHIBITING NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVITY | GLO PHARMA, INC. | 2021-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210324006-A1 | PEPTIDE COMPOSITIONS AND METHODS FOR INHIBITING NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVITY | CHRNB1, CHRNG, CHRNA1 | ALDH1A1 4790/4885FOLH1 1743/4885ALB 4556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.